



"Disruption to Opportunity" The Next Digital Frontier for Medical Affairs and Healthcare with the New Normal



Executive Director, Head of IT for Global Medical Affairs, Bristol Myers Squibb

Panel Members



Shaji Kalathil Executive Director, Head of IT for Global Medical Affairs, Bristol Myers Squibb

MAPS Digital Strategy FAWG Co-Lead Moderator



Joseph Eid, MD Senior Vice President, Head of Global Medical Affairs, Bristol Myers Squibb



David Rhew, MD Chief Medical Officer & VP of Healthcare, Worldwide Commercial Business, Microsoft



Paul Shawah Senior Vice President, Commercial Cloud Strategy, Veeva Systems



Executive Director, Head of IT for Global Medical Affairs, Bristol Myers Squibb

Session Objectives

- Discuss emerging trends and viewpoints on the next frontier for digital in Medical Affairs and the broader healthcare environment with the "New Normal"
- Explore "outside-in" views on how leading technology companies are addressing the COVID-19 scenario with new approaches across pharma and other industries
- Identify how the disruption can be turned into opportunities and differentiating strategies



Executive Director, Head of IT for Global Medical Affairs, Bristol Myers Squibb

Housekeeping

Questions for Presenters:

 Please submit questions throughout the presentation using the Q&A button in your control panel.

Evaluations:

• The control panel includes a webinar evaluation. Please complete that evaluation so that we can work to ensure the highest quality presentations.

On-demand Availability of Webinar:

• This webinar, as with all previous ones, will be available on-demand next week in the Community Portal for MAPS members.



Executive Director, Head of IT for Global Medical Affairs, Bristol Myers Squibb

Disclaimer

The views expressed in this Webinar are those of the presenters, and are not an official position statement by MAPS, nor do they necessarily represent the views of the MAPS organization or its members.

This presentation is for informational purposes only and is not intended as legal or regulatory advice.



>> NOW SPEAKING: Shaji Kalathil Executive Director, Head of IT for Global Medical Affairs, Bristol Myers Squibb

Acceleration of Digital Transformation in Life Sciences with COVID-19 It is Now Time to Seize Our Digital Moment





New Normal for Medical Affairs A View into the Future through the Digital Lens

Joseph Eid, MD, Senior Vice President, Head of Global Medical Affairs Bristol Myers Squibb



>> NOW SPEAKING: Joseph Eid, MD

Senior Vice President, Head of Global Medical Affairs, Bristol Myers Squibb

The Silver Lining of COVID-19 for Medical Affairs : Accelerated Change







Digital First More Digitally Savvy Increased Agility More Adaptive Deeper Analytics *Right Data, Right Time*


The Pandemic Has Forced Us to Adapt & Adopt



>> NOW SPEAKING: Joseph Eid, MD

Senior Vice President, Head of Global Medical Affairs, Bristol Myers Squibb

As the Post Pandemic World Begins to Settle....



THE NEW NORMAL



>> NOW SPEAKING: Joseph Eid, MD

Senior Vice President, Head of Global Medical Affairs, Bristol Myers Squibb

Medical Affairs Professional in the New Normal

Proactive, strategic leader

Healthcare system focused (provider, payer, gov/policy, patient, pathway organizations)

Holistic global perspective that enables market-level decision making



Personalized, multi-channel interactions (in-person & virtual)

> End-to-end knowledge provider (science, "value", technology-powered interactions)

> > Proactively capturing, providing, managing, and analyzing data

Empowered by Digital & Equipped for Future Success



COVID-19 Healthcare Experience – Emerging Trends and Disruption Opportunities

David Rhew, MD Chief Medical Officer & VP of Healthcare Worldwide Commercial Business Microsoft



Chief Medical Officer & VP of Healthcare, Worldwide Commercial Business, Microsoft

COVID-19 Response: Technology Enablers



Chatbot

- Screening & Triage
- Clinical trial enrollment
- Donor recruitment
- CDS for front-line
 agents



Virtual Care

- Tele-medicine
- Tele-ICU
- Virtual rounding
- Virtual sign-outs
- Virtual consults
- Virtual surgery
- Virtual tumor board




AI & Performance Computing

- Supercomputers
- Cloud-scale
- Al modeling
- Drug/vaccine
 targets
- Accelerated drug/vaccine discovery



Data Platforms

- COVID-19 Healthcare Coalition
- Centralized data platforms



Contact Tracing

• Case

٠

- management
- Memory-assist
- Proximity awareness



What's Next?


- Rapid test kits
- Testing strategies
- RTW/RTS
- Vaccine distribution



Chief Medical Officer & VP of Healthcare, Worldwide Commercial Business, Microsoft

restart

The fight is in Us



HOW IS BLOOD PLASMA USED?

Plasma from those who have recovered could be a key part of the fight against COVID-I9. Once the COVID-I9 plasma is donated, it can take one of two paths: be directly transfused into patients or be used to make a potential medicine.

THE FIGHT IS IN US

A coalition of world-leading medical and research institutions, blood centers, life science companies, technology companies, philanthropic organizations, and survivor groups has come together to support the rapid development of potential new therapies for COVID-19 patients. These therapies use blood plasma donated by people who have fully recovered from COVID-19, since their blood may have antibodies from their immune response to the virus.

You are invited to voluntarily answer the non-personally identifiable questions below ("Inquiry Form") to see if you are eligible to be a potential donor. If you are eligible, you may enter a ZIP code to see the closest donor centers near you. For more information about how your privacy is protected, please see the Privacy Policy. For other questions see FAQs.

This Inquiry Form is not designed or intended to be a substitute for, nor should it be used to replace professional medical advice, diagnosis, treatment, or judgment.


Do you accept these terms?



Chief Medical Officer & VP of Healthcare, Worldwide Commercial Business, Microsoft

Virtual Rounding





Reduced exposure by 51% (*P*=.002)

Reduced PPE usage by 83% (*P*=.02)

Martin G et al. JMIR. 22(8). Aug 2020



Chief Medical Officer & VP of Healthcare, Worldwide Commercial Business, Microsoft

Cloud-scale machine learning to translate T-cells to antigens



Blood Sample

Our immune system is a very sophisticated diagnostic machine

Immunusequencing

Reading every immune cell that stores diagnostic information

Machine Learning

Generating a map of the immune system by matching trillions of T cells to the diseases they recognize

Empowered Care


This map of the immune system will be used by doctors and researchers around the world to understand the disease



Chief Medical Officer & VP of Healthcare, Worldwide Commercial Business, Microsoft


Drug Discovery Today Volume 24, Issue 3, March 2019, Pages 773-780 Artificial intelligence in drug development: present status and future prospects

Kit-Kay Mak ^{1, 2}, Mallikarjuna Rao Pichika ^{2, 3} $\stackrel{>}{\sim}$ 🖾






Chief Medical Officer & VP of Healthcare, Worldwide Commercial Business, Microsoft





Chief Medical Officer & VP of Healthcare, Worldwide Commercial Business, Microsoft





Chief Medical Officer & VP of Healthcare, Worldwide Commercial Business, Microsoft

COVID-19 Healthcare Coalition

Supply Chain

DELIVERED 675,000 masks

VALIDATED N95 mask

decontamination strategies

DEVELOPED PPE demand model

CONNECTED suppliers to buyers

DEVELOPING the COVID-19 Decision Support Dashboard

Coordinated

Social Policies

PROVIDING insights on the impact of social policies

PROMOTING innovation in testing and contact tracing

UNLOCKING large-scale analytics for COVID-19

Data-Driven

Clinical Insights

ADVANCING convalescent plasma research

COLLABORATING on best practices and protocols

Medic

Tech Collaboration

BUILT critical infrastructure to enable collaboration and shared analytics

LAUNCHED public website with useful decision aids dashboards

CONVENED leading technology firms in service of the public interest



COVID 19 Pharma Experience – An "Outside In View" on Customer Engagement Trends & Path Forward

Paul Shawah Senior Vice President, Commercial Cloud Strategy Veeva Systems



Senior Vice President, Commercial Cloud Strategy, Veeva Systems

The Golden Age of Medical


Growing Importance of Medical Affairs....

Disrupted, or Strengthened by COVID-19?



Senior Vice President, Commercial Cloud Strategy, Veeva Systems


Accelerated Shift to Digital





Senior Vice President, Commercial Cloud Strategy, Veeva Systems


Greater Access, Deeper Engagement





Senior Vice President, Commercial Cloud Strategy, Veeva Systems


Mix Will Evolve Over Time





Senior Vice President, Commercial Cloud Strategy, Veeva Systems


Digital Creates Opportunity





Senior Vice President, Commercial Cloud Strategy, Veeva Systems

...But Digital Also Creates Stress





Senior Vice President, Commercial Cloud Strategy, Veeva Systems

Key Imperatives for Leaders

Embrace shift to broad, person specific channel mix Use personal relationships to drive two-way engagement Surface personalized, curated scientific content Efficiently capture and analyze key medical insights Efficiently surface new insights and notifications Create a modular, efficient content strategy





Shaji Kalathil Executive Director, Head of IT for Global Medical Affairs, Bristol Myers Squibb



Joseph Eid, MD Senior Vice President, Head of Global Medical Affairs, Bristol Myers Squibb



David Rhew, MD Chief Medical Officer & VP of Healthcare, Worldwide Commercial Business, Microsoft



Paul Shawah Senior Vice President, Commercial Cloud Strategy, Veeva Systems

Thank you! Questions?